Which type of obesity benefits most from endoscopic intragastric balloon application?

Year 2025, Volume: 11 Issue: 2, 412 - 419, 04.03.2025

Azad Gazi Şahin , Erman Alçı

https://doi.org/10.18621/eurj.1627917

Abstract

Objectives: As obesity poses significant health risks, exploring minimally invasive treatments like intragastric balloons becomes crucial for enhanced accessibility and efficacy in managing this pervasive public health challenge. This retrospective study aimed to evaluate the effectiveness of Intragastric Balloon (IGB) application in weight reduction across various degrees of obesity, providing a comprehensive assessment of its efficacy.

Methods: A total of 187 patients with a BMI >30 kg/m2 underwent IGB application and were categorized into three groups based on the degree of obesity. Statistical analyses were conducted to assess weight loss, excess weight loss, and BMI reduction, focusing on the impact of IGB therapy in different degrees of obesity.

Results: IGB application demonstrated significant efficacy in weight reduction across all degrees of obesity. Notably, the highest rates of excess weight loss were observed in patients with Class 1 obesity. Gender-specific analysis revealed variations in the response to IGB therapy, with females exhibiting higher success rates.

Conclusions: The findings of this study highlight the efficacy of IGB application in achieving weight loss, emphasizing its effectiveness across different degrees of obesity. The notable success in Class 1 obesity underscores the potential of IGB as an effective treatment modality.

Keywords

Gastric balloon, obesity, obesity management, weight loss

Ethical Statement

This study was approved by the Clinical Research Ethics Committeeof Balıkesir University School of Medicine (Decision date: 22.11.2023 and no. 2023/179).

References

• 1. Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond). 2008;32(6):959-966. doi: 10.1038/ijo.2008.11.
• 2. Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(7 Suppl):s176-85.
• 3. Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6-10. doi: 10.1016/j.metabol.2018.09.005.
• 4. World Health Organization. Obesity and overweight fact sheet. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed September 10, 2023.
• 5. Cooper AJ, Gupta SR, Moustafa AF, Chao AM. Sex/Gender Differences in Obesity Prevalence, Comorbidities, and Treatment. Curr Obes Rep. 2021;10(4):458-466. doi: 10.1007/s13679-021-00453-x.
• 6. Müller TD, Blüher M. [Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?]. Inn Med (Heidelb). 2023;64(7):629-635. doi: 10.1007/s00108-023-01530-0. [Article in German]
• 7. Orzano AJ, Scott JG. Diagnosis and treatment of obesity in adults: an applied evidence-based review. J Am Board Fam Pract. 2004;17(5):359-369. doi: 10.3122/jabfm.17.5.359.
• 8. Kim SH, Chun HJ, Choi HS, Kim ES, Keum B, Jeen YT. Current status of intragastric balloon for obesity treatment. World J Gastroenterol. 2016;22(24):5495-5504. doi: 10.3748/wjg.v22.i24.5495.
• 9. Silva LB, Neto MG. Intragastric balloon. Minim Invasive Ther Allied Technol. 2022;31(4):505-514. doi: 10.1080/13645706.2021.1874420.
• 10. Crossan K, Sheer AJ. Intragastric Balloon. 2023 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
• 11. Cho JH, Bilal M, Kim MC, Cohen J; Study Group for Endoscopic Bariatric and Metabolic Therapies of the Korean Society of Gastrointestinal Endoscopy. The Clinical and Metabolic Effects of Intragastric Balloon on Morbid Obesity and Its Related Comorbidities. Clin Endosc. 2021;54(1):9-16. doi: 10.5946/ce.2020.302.
• 12. Żurawiński W, Sokołowski D, Krupa-Kotara K, Czech E, Sosada K. Evaluation of the results of treatment of morbid obesity by the endoscopic intragastric balloon implantation method. Wideochir Inne Tech Maloinwazyjne. 2017;12(1):37-48. doi: 10.5114/wiitm.2017.66856.
• 13. Srisuworanan N, Suwatthanarak T, Chinswangwatanakul V, et al. Surgical outcomes of bariatric surgery in Siriraj Hospital for the first 100 morbidly obese patients treated. Siriraj Med J. 2022;74(11):769-77. doi: 10.33192/Smj.2022.91.
• 14. Fittipaldi-Fernandez RJ, Zotarelli-Filho IJ, Diestel CF, et al. Intragastric Balloon: a Retrospective Evaluation of 5874 Patients on Tolerance, Complications, and Efficacy in Different Degrees of Overweight. Obes Surg. 2020;30(12):4892-4898. doi: 10.1007/s11695-020-04985-4.
• 15. Imaz I, Martínez-Cervell C, García-Alvarez EE, Sendra-Gutiérrez JM, González-Enríquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841-846. doi: 10.1007/s11695-007-9331-8.
• 16. Suchartlikitwong S, Laoveeravat P, Mingbunjerdsuk T, et al. Usefulness of the ReShape intragastric balloon for obesity. Proc (Bayl Univ Med Cent). 2019;32(2):192-195. doi: 10.1080/08998280.2018.1559397.
• 17. Nunes GC, Pajecki D, de Melo ME, Mancini MC, de Cleva R, Santo MA. Assessment of Weight Loss With the Intragastric Balloon in Patients With Different Degrees of Obesity. Surg Laparosc Endosc Percutan Tech. 2017;27(4):e83-e86. doi: 10.1097/SLE.0000000000000440.